2012 Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Syndrome

Mary-Ann Fitzcharles1,2, Peter A. Ste-Marie2,3, Don L. Goldenberg4, John X. Pereira5, Susan Abbey6, Manon Choinière7, Gordon Ko8, Dwight Moulin9, Pantelis Panopalis1, Johanne Proulx10, Yoram Shir2

1.      Wolfe, F., et al., The American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism, 1990. 33(2): p. 160-172.

2.      Wolfe, F., et al., The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis care & research, 2010. 62(5): p. 600-10.

3.      Mease, P., et al., Fibromyalgia syndrome module at OMERACT 9: domain construct. Journal of Rheumatology, 2009. 36(10): p. 2318-29.

4.      McNally, J.D., D.A. Matheson, and V.S. Bakowsky, The epidemiology of self-reported fibromyalgia in Canada. Chronic Dis Can, 2006. 27(1): p. 9-16.

5.      Lachaine, J., C. Beauchemin, and P.-A. Landry, Clinical and economic characteristics of patients with fibromyalgia syndrome. Clinical Journal of Pain, 2010. 26(4): p. 284-90.

6.      Hughes, G., et al., The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis & Rheumatism, 2006. 54(1): p. 177-83.

7.      Carville, S.F., et al., EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases, 2008. 67(4): p. 536-41.

8.      Hauser, W., et al., Fibromyalgia syndrome: classification, diagnosis, and treatment. Deutsches Arzteblatt International, 2009. 106(23): p. 383-91.

9.      Burckhardt, C., Goldenberg, D., Crofford, L., Gerwin, R., Gowans, S., Kackson, et al., Guideline for the management of fibromyalgia syndrome. Pain in adults and children. APS Clinical practice guideline Series No. 4 Glenview, IL: American Pain Society; 2005.

10.    Howick, J., Chalmers, I., Glasziou, P., Greenhalgh, T., Heneghan, C., Liberati, A., Moschetti, I., Phillips, B., Thornton, H., Goddard, O., Hodgkinson, M., The Oxford 2011 Table of Evidence. Oxford Centre for Evidence-Based Medicine.


11.    Yunus, M.B., A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheumatic Diseases Clinics of North America, 2002. 28(2): p. 201-17.

12.    Wolfe, F., et al., Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis & Rheumatism, 1997. 40(9): p. 1571-9.

13.    Walitt, B., et al., The longitudinal outcome of fibromyalgia: a study of 1555 patients. Journal of Rheumatology, 2011. 38(10): p. 2238-46.

14.    Rehm, S.E., et al., A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology, 2010. 49(6): p. 1146-52.

15.    Simms, R.W. and D.L. Goldenberg, Symptoms mimicking neurologic disorders in fibromyalgia syndrome. Journal of Rheumatology, 1988. 15(8): p. 1271-3.

16.    Hagglund, K.J., et al., Weather, beliefs about weather, and disease severity among patients with fibromyalgia. Arthritis Care and Research, 1994. 7 (3): p. 130-135.

17.    Macfarlane, T.V., et al., Whether the weather influences pain? Results from the EpiFunD study in North West England. Rheumatology, 2010. 49(8): p. 1513-20.

18.    Mease, P., et al., Fibromyalgia syndrome. Journal of Rheumatology, 2007. 34(6): p. 1415-25.

19.    Yunus, M.B., Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Seminars in Arthritis & Rheumatism, 2007. 36(6): p. 339-56.

20.    Chiu, Y.H., et al., Poor sleep and depression are independently associated with a reduced pain threshold. Results of a population based study. Pain, 2005. 115(3): p. 316-21.

21.    Osorio, C.D., et al., Sleep quality in patients with fibromyalgia using the Pittsburgh Sleep Quality Index. Journal of Rheumatology, 2006. 33(9): p. 1863-5.

22.    Moldofsky, H., The significance of the sleeping-waking brain for the understanding of widespread musculoskeletal pain and fatigue in fibromyalgia syndrome and allied syndromes. Joint Bone Spine, 2008. 75(4): p. 397-402.

23.    Hamilton, N.A., et al., Fibromyalgia: the role of sleep in affect and in negative event reactivity and recovery. Health Psychol, 2008. 27(4): p. 490-7.

24.    Moldofsky, H., et al., Effects of Bedtime Very Low Dose Cyclobenzaprine on Symptoms and Sleep Physiology in Patients with Fibromyalgia Syndrome: A Double-blind Randomized Placebo-controlled Study. Journal of Rheumatology, 2011. 38(12): p. 2653-63.

25.    Gore, M., et al., Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ, 2012. 15(1): p. 32-44.

26.    Pauer, L., et al., An International, Randomized, Double-blind, Placebo-controlled, Phase III Trial of Pregabalin Monotherapy in Treatment of Patients with Fibromyalgia. Journal of Rheumatology, 2011. 38(12): p. 2643-2652.

27.    Canovas, R., et al., Virtual reality tasks disclose spatial memory alterations in fibromyalgia. Rheumatology, 2009. 48(10): p. 1273-8.

28.    Park, D.C., et al., Cognitive function in fibromyalgia patients. Arthritis & Rheumatism, 2001. 44(9): p. 2125-33.

29.    Rodriguez-Andreu, J., et al., Cognitive impairment in patients with fibromyalgia syndrome as assessed by the mini-mental state examination. BMC Musculoskeletal Disorders, 2009. 10: p. 162.

30.    Walitt, B., et al., Automated neuropsychiatric measurements of information processing in fibromyalgia. Rheumatology International, 2008. 28(6): p. 561-6.

31.    Epstein, S.A., et al., Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics, 1999. 40(1): p. 57-63.

32.    de Souza, J.B., et al., Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatology International, 2009. 29(5): p. 509-15.

33.    Thieme, K., D.C. Turk, and H. Flor, Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med, 2004. 66(6): p. 837-44.

34.    Nicassio, P.M., et al., The contribution of family cohesion and the pain-coping process to depressive symptoms in fibromyalgia. Annals of Behavioral Medicine, 1995. 17(4): p. 349-356.

35.    Raphael, K.G., et al., Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain, 2004. 110(1-2): p. 449-60.

36.    de Araujo, M.P., et al., Urodynamic study and quality of life in patients with fibromyalgia and lower urinary tract symptoms. Int Urogynecol J Pelvic Floor Dysfunct, 2008. 19(8): p. 1103-7.

37.    Dao, T.T., W.J. Reynolds, and H.C. Tenenbaum, Comorbidity between myofascial pain of the masticatory muscles and fibromyalgia. J Orofac Pain, 1997. 11(3): p. 232-41.

38.    Plesh, O., F. Wolfe, and N. Lane, The relationship between fibromyalgia and temporomandibular disorders: Prevalence and symptom severity. Journal of Rheumatology, 1996. 23(11): p. 1948-1952.

39.    Poyhia, R., D. Da Costa, and M.A. Fitzcharles, Previous pain experience in women with fibromyalgia and inflammatory arthritis and nonpainful controls. Journal of Rheumatology, 2001. 28(8): p. 1888-91.

40.    Orellana, C., et al., Sexual dysfunction in fibromyalgia patients. Clinical & Experimental Rheumatology, 2008. 26(4): p. 663-6.

41.    Roy-Byrne, P., et al., Post-traumatic stress disorder among patients with chronic pain and chronic fatigue. Psychological Medicine, 2004. 34(2): p. 363-368.

42.    Lipworth, L., R.E. Tarone, and J.K. McLaughlin, Breast implants and fibromyalgia: a review of the epidemiologic evidence. Annals of Plastic Surgery, 2004. 52(3): p. 284-7.

43.    Wolfe, F., “Silicone related symptoms” are common in patients with fibromyalgia: No evidence for a new disease. Journal of Rheumatology, 1999. 26(5): p. 1172-1175.

44.    Weingarten, T.N., et al., Impact of tobacco use in patients presenting to a multidisciplinary outpatient treatment program for fibromyalgia. Clinical Journal of Pain, 2009. 25(1): p. 39-43.

45.    Walitt, B., et al., The Longitudinal Outcome of Fibromyalgia: A Study of 1555 Patients. J Rheumatol, 2011.

46.    Mease, P., et al., Fibromyalgia syndrome module at OMERACT 9: Domain construct. J Rheumatol, 2009. 36(10): p. 2318-2329.

47.    Gervais, R.O., et al., Effort testing in patients with fibromyalgia and disability incentives. J Rheumatol, 2001. 28(8): p. 1892-9.

48.    Croft, P., Testing for tenderness: what’s the point? Journal of Rheumatology, 2000. 27(11): p. 2531-3.

49.    Tunks, E., et al., The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. Journal of Rheumatology, 1995. 22(5): p. 944-52.

50.    Cott, A., et al., Interrater reliability of the tender point criterion for fibromyalgia. Journal of Rheumatology, 1992. 19(12): p. 1955-9.

51.    Jacobs, J.W., et al., Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care & Research, 1996. 9(2): p. 105-11.

52.    Lundberg, G. and B. Gerdle, Tender point scores and their relations to signs of mobility, symptoms, and disability in female home care personnel and the prevalence of fibromyalgia syndrome. Journal of Rheumatology, 2002. 29(3): p. 603-13.

53.    McCarberg, B., et al., Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. American Journal of Therapeutics, 2003. 10(3): p. 176-92.

54.    McIntosh, M.J., et al., Protocol for verifying expertise in locating fibromyalgia tender points. Arthritis Care & Research, 1998. 11(3): p. 210-6.

55.    McVeigh, J.G., et al., Tender point count and total myalgic score in fibromyalgia: changes over a 28-day period. Rheumatology International, 2007. 27(11): p. 1011-8.

56.    Harth, M. and W.R. Nielson, The fibromyalgia tender points: use them or lose them? A brief review of the controversy. Journal of Rheumatology, 2007. 34(5): p. 914-22.

57.    Okifuji, A., et al., A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. Journal of Rheumatology, 1997. 24(2): p. 377-83.

58.    Bidari, A., B. Ghavidel-Parsa, and B. Ghalehbaghi, Reliability of ACR criteria over time to differentiate classic fibromyalgia from nonspecific widespread pain syndrome: a 6-month prospective cohort study. Mod Rheumatol, 2009. 19(6): p. 663-9.

59.    Jespersen, A., et al., Computerized cuff pressure algometry: A new method to assess deep-tissue hypersensitivity in fibromyalgia. Pain, 2007. 131(1-2): p. 57-62.

60.    Wolfe, F. and W. Hauser, Fibromyalgia diagnosis and diagnostic criteria. Annals of Medicine, 2011. 43(7): p. 495-502.

61.    Tastekin, N., M. Birtane, and K. Uzunca, Which of the three different tender points assessment methods is more useful for predicting the severity of fibromyalgia syndrome? Rheumatology International, 2007. 27(5): p. 447-51.

62.    Petzke, F., et al., What do tender points measure? Influence of distress on 4 measures of tenderness. Journal of Rheumatology, 2003. 30(3): p. 567-74.

63.    Tastekin, N., et al., Discriminative value of tender points in fibromyalgia syndrome. Pain Medicine, 2010. 11(3): p. 466-71.

64.    Khostanteen, I., et al., Fibromyalgia: Can one distinguish it from simulation? An observer-blind controlled study. Journal of Rheumatology, 2000. 27(11): p. 2671-2676.

65.    Eich, W., et al., [Definition, classification and diagnosis of fibromyalgia syndrome]. Schmerz, 2008. 22(3): p. 255-66.

66.    Katz, R.S., F. Wolfe, and K. Michaud, Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum, 2006. 54(1): p. 169-76.

67.    Russell, I.J., Fibromyalgia syndrome: Presentation, diagnosis, and differential diagnosis. Primary Psychiatry, 2006. 13(9): p. 40-45.

68.    Daniel, D. and M.V. Pirotta, Fibromyalgia–should we be testing and treating for vitamin D deficiency? Australian family physician, 2011. 40(9): p. 712-6.

69.    Tandeter, H., et al., Serum 25-OH vitamin D levels in patients with fibromyalgia. Isr Med Assoc J, 2009. 11(6): p. 339-42.

70.    Warner, A.E. and S.A. Arnspiger, Diffuse musculoskeletal pain is not associated with low vitamin D levels or improved by treatment with vitamin D. J Clin Rheumatol, 2008. 14(1): p. 12-6.

71.    Al-Allaf, A.W., L. Ottewell, and T. Pullar, The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years’ follow-up. Clinical Rheumatology, 2002. 21(6): p. 472-7.

72.    Kotter, I., et al., Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatology International, 2007. 27(11): p. 1031-9.

73.    Yunus, M.B., F.X. Hussey, and J.C. Aldag, Antinuclear antibodies and connective tissue disease features in fibromyalgia syndrome: a controlled study. Journal of Rheumatology, 1993. 20(9): p. 1557-60.

74.    Landis, C.A., et al., Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain, Behavior, & Immunity, 2004. 18(4): p. 304-13.

75.    Yunus, M.B., et al., Fibromyalgia syndrome: Clinical features and spectrum. Journal of Musculoskeletal Pain, 1994. 2(3): p. 5-21.

76.    Goldenberg, D.L., Diagnosis and differential diagnosis of fibromyalgia. Am J Med, 2009. 122(12 Suppl): p. S14-21.

77.    Shir, Y. and M.-A. Fitzcharles, Should rheumatologists retain ownership of fibromyalgia? Journal of Rheumatology, 2009. 36(4): p. 667-70.

78.    Buskila, D., et al., Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Family Practice, 1997. 14(3): p. 238-41.

79.    Wolfe, F., Stop using the American College of Rheumatology criteria in the clinic. Journal of Rheumatology, 2003. 30(8): p. 1671-2.

80.    Katz, J.D., et al., Gender bias in diagnosing fibromyalgia. Gend Med, 2010. 7(1): p. 19-27.

81.    Coster, L., et al., Chronic widespread musculoskeletal pain – a comparison of those who meet criteria for fibromyalgia and those who do not. European Journal of Pain: Ejp, 2008. 12(5): p. 600-10.

82.    Annemans, L., et al., Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis & Rheumatism, 2008. 58(3): p. 895-902.

83.    Annemans, L., K. Le Lay, and C. Taieb, Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics, 2009. 27(7): p. 547-59.

84.    Norregaard, J., et al., A four-year follow-up study in fibromyalgia. Relationship to chronic fatigue syndrome. Scandinavian Journal of Rheumatology, 1993. 22(1): p. 35-8.

85.    Wolfe, F., Fibromyalgia: On diagnosis and certainty. Journal of Musculoskeletal Pain, 1993. 1(3-4): p. 17-35.

86.    Fitzcharles, M.A. and J.M. Esdaile, The overdiagnosis of fibromyalgia syndrome. American Journal of Medicine, 1997. 103(1): p. 44-50.

87.    Fitzcharles, M.A. and P. Boulos, Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford), 2003. 42(2): p. 263-7.

88.    Schneider, M.J., Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. Journal of Manipulative & Physiological Therapeutics, 1995. 18(6): p. 398-406.

89.    Fassbender, K., et al., Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clinical Rheumatology, 1997. 16(1): p. 76-9.

90.    Hsu, V.M., S.J. Patella, and L.H. Sigal, “Chronic Lyme disease” as the incorrect diagnosis in patients with fibromyalgia. Arthritis & Rheumatism, 1993. 36(11): p. 1493-500.

91.    Kozanoglu, E., et al., Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatology International, 2003. 23(5): p. 248-251.

92.    Abd, T.T. and T.A. Jacobson, Statin-induced myopathy: a review and update. Expert Opin Drug Saf, 2011. 10(3): p. 373-87.

93.    Henry, N.L., et al., A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer, 2010. 116(18): p. 4360-7.

94.    Papapetrou, P.D., Bisphosphonate-associated adverse events. Hormones (Athens), 2009. 8(2): p. 96-110.

95.    White, K.P., et al., Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis & Rheumatism, 2002. 47(3): p. 260-5.

96.    Shleyfer, E., et al., Accuracy of the diagnosis of fibromyalgia by family physicians: is the pendulum shifting? Journal of Rheumatology, 2009. 36(1): p. 170-3.

97.    Garcia-Campayo, J., et al., A meta-analysis of the efficacy of fibromyalgia treatment according to level of care. Arthritis Res Ther, 2008. 10(4): p. R81.

98.    White, L.A., et al., Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. Journal of Pain, 2009. 10(9): p. 976-83.

99.    Zih, F.S.W., D. Da Costa, and M.-A. Fitzcharles, Is there benefit in referring patients with fibromyalgia to a specialist clinic? Journal of Rheumatology, 2004. 31(12): p. 2468-71.

100.  Kroese, M.E.A.L., et al., Therapeutic approaches to fibromyalgia in the Netherlands: a comparison between 1998 and 2005. Journal of Evaluation in Clinical Practice, 2008. 14(2): p. 321-5.

101.  Kroese, M.E., et al., Substitution of specialized rheumatology nurses for rheumatologists in the diagnostic process of fibromyalgia: a randomized controlled trial. Arthritis Rheum, 2008. 59(9): p. 1299-305.

102.  Becker, H., et al., The use of goal attainment scaling to facilitate and assess individualized change in a wellness intervention for women with fibromyalgia syndrome. Journal of Holistic Nursing, 2009. 27(4): p. 232-40.

103.  Hellstrom, O., et al., Doctors’ attitudes to fibromyalgia: a phenomenological study. Scandinavian Journal of Social Medicine, 1998. 26(3): p. 232-7.

104.  Ehrlich, G.E., Fibromyalgia, a virtual disease. Clinical Rheumatology, 2003. 22(1): p. 8-11.

105.  Hazemeijer, I. and J.J. Rasker, Fibromyalgia and the therapeutic domain. A philosophical study on the origins of fibromyalgia in a specific social setting. Rheumatology, 2003. 42(4): p. 507-15.

106.  Walker, E.A., et al., Predictors of physician frustration in the care of patients with rheumatological complaints. General Hospital Psychiatry, 1997. 19(5): p. 315-23.

107.  Haugli, L., E. Strand, and A. Finset, How do patients with rheumatic disease experience their relationship with their doctors? A qualitative study of experiences of stress and support in the doctor-patient relationship. Patient Education & Counseling, 2004. 52(2): p. 169-74.

108.  Dobkin, P.L., et al., Patient-physician discordance in fibromyalgia. Journal of Rheumatology, 2003. 30(6): p. 1326-34.

109.  Asbring, P. and A.-L. Narvanen, Ideal versus reality: physicians perspectives on patients with chronic fatigue syndrome (CFS) and fibromyalgia. Social Science & Medicine, 2003. 57(4): p. 711-20.

110.  Bieber, C., et al., A shared decision-making communication training program for physicians treating fibromyalgia patients: effects of a randomized controlled trial. Journal of Psychosomatic Research, 2008. 64(1): p. 13-20.

111.  Perrot, S., A.H. Dickenson, and R.M. Bennett, Fibromyalgia: harmonizing science with clinical practice considerations. Pain Practice, 2008. 8(3): p. 177-89.

112.  Abeles, A.M., et al., Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med, 2007. 146(10): p. 726-34.

113.  Gracely, R.H., M.A.B. Grant, and T. Giesecke, Evoked pain measures in fibromyalgia. Best Practice & Research in Clinical Rheumatology, 2003. 17(4): p. 593-609.

114.  Staud, R., Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Res Ther, 2006. 8(3): p. 208.

115.  Gracely, R.H., et al., Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum, 2002. 46(5): p. 1333-43.

116.  Petzke, F. and D.J. Clauw, Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep, 2000. 2(2): p. 116-23.

117.  Price, D.D. and R. Staud, Neurobiology of fibromyalgia syndrome. Journal of Rheumatology – Supplement, 2005. 75: p. 22-8.

118.  Julien, N., et al., Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain, 2005. 114(1-2): p. 295-302.

119.  Buskila, D. and L. Neumann, Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. Journal of Rheumatology, 1997. 24(5): p. 941-4.

120.  Buskila, D., et al., Familial aggregation in the fibromyalgia syndrome. Seminars in Arthritis & Rheumatism, 1996. 26(3): p. 605-11.

121.  McBeth, J., et al., Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain – Findings of a population-based prospective cohort study. Arthritis and Rheumatism, 2007. 56(1): p. 360-371.

122.  Smith, S.B., et al., Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum, 2011.

123.  Buskila, D. and P. Sarzi-Puttini, Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther, 2006. 8(5): p. 218.

124.  Gupta, A., et al., The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford), 2007. 46(4): p. 666-71.

125.  Gormsen, L., et al., Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. European Journal of Pain: Ejp, 2010. 14(2): p. 127 e1-8.

126.  Jones, G.T., C. Power, and G.J. Macfarlane, Adverse events in childhood and chronic widespread pain in adult life: Results from the 1958 British Birth Cohort Study. Pain, 2009. 143(1-2): p. 92-6.

127.  Pae, C.U., et al., History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. World J Biol Psychiatry, 2009. 10(4 Pt 2): p. 435-41.

128.  Ruiz-Perez, I., et al., Risk factors for fibromyalgia: the role of violence against women. Clin Rheumatol, 2009. 28(7): p. 777-86.

129.  Boisset-Pioro, M.H., J.M. Esdaile, and M.A. Fitzcharles, Sexual and physical abuse in women with fibromyalgia syndrome. Arthritis & Rheumatism, 1995. 38(2): p. 235-41.

130.  Greenfield, S., M.A. Fitzcharles, and J.M. Esdaile, Reactive fibromyalgia syndrome. Arthritis & Rheumatism, 1992. 35(6): p. 678-81.

131.  Boomershine, C.S. and L.J. Crofford, A symptom-based approach to pharmacologic management of fibromyalgia. Nature Reviews Rheumatology, 2009. 5(4): p. 191-9.

132.  Rossy, L.A., et al., A meta-analysis of fibromyalgia treatment interventions. Annals of Behavioral Medicine, 1999. 21(2): p. 180-91.

133.  Dobkin, P.L., et al., Predictors of disability and pain six months after the end of treatment for fibromyalgia. Clinical Journal of Pain, 2010. 26(1): p. 23-9.

134.  Giesecke, T., et al., Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis & Rheumatism, 2003. 48(10): p. 2916-22.

135.  Turk, D.C., et al., Pain, disability, and physical functioning in subgroups of patients with fibromyalgia. Journal of Rheumatology, 1996. 23(7): p. 1255-62.

136.  Rutledge, D.N., M. Mouttapa, and P.B. Wood, Symptom clusters in fibromyalgia: potential utility in patient assessment and treatment evaluation. Nursing Research, 2009. 58(5): p. 359-67.

137.  Hauser, W., et al., Efficacy of multicomponent treatment in fibromyalgia syndrome: a meta-analysis of randomized controlled clinical trials. Arthritis & Rheumatism, 2009. 61(2): p. 216-24.

138.  Goldenberg, D.L., C. Burckhardt, and L. Crofford, Management of fibromyalgia syndrome. JAMA, 2004. 292(19): p. 2388-95.

139.  Karsdorp, P.A. and J.W. Vlaeyen, Active avoidance but not activity pacing is associated with disability in fibromyalgia. Pain, 2009. 147(1-3): p. 29-35.

140.  Torres, X., et al., Pain locus of control predicts return to work among Spanish fibromyalgia patients after completion of a multidisciplinary pain program. General Hospital Psychiatry, 2009. 31(2): p. 137-45.

141.  Beal, C.C., A.K. Stuifbergen, and A. Brown, Predictors of a health promoting lifestyle in women with fibromyalgia syndrome. Psychology Health & Medicine, 2009. 14(3): p. 343-53.

142.  Du Plessis, M., H.R. Steel, and A.T. Moller, The relationship between psychosocial variables and measures of health status in fibromyalgia. South African Family Practice, 2009. 51(1): p. 42-45.

143.  Henriksson, C. and C. Burckhardt, Impact of fibromyalgia on everyday life: a study of women in the USA and Sweden. Disability & Rehabilitation, 1996. 18(5): p. 241-8.

144.  Henriksson, C. and G. Liedberg, Factors of importance for work disability in women with fibromyalgia. Journal of Rheumatology, 2000. 27(5): p. 1271-6.

145.  Garcia-Campayo, J., et al., Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. Trials [Electronic Resource], 2009. 10: p. 24.

146.  Bernatsky, S., et al., Co-morbidity and physician use in fibromyalgia. Swiss Medical Weekly, 2005. 135(5-6): p. 76-81.

147.  Ciapparelli, A., et al., The impact of psychiatric comorbidity on health-related quality of life in women with fibromyalgia. Clinical Neuropsychiatry, 2008. 5(5): p. 217-224.

148.  Dobkin, P.L., et al., Predictors of health status in women with fibromyalgia: a prospective study. Int J Behav Med, 2006. 13(2): p. 101-8.

149.  Hughes, L., Physical and psychological variables that influence pain in patients with fibromyalgia. Orthopaedic Nursing, 2006. 25(2): p. 112-9.

150.  Bennett, R. and D. Nelson, Cognitive behavioral therapy for fibromyalgia. Nat Clin Pract Rheumatol, 2006. 2(8): p. 416-24.

151.  Bernardy, K., et al., Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome – a systematic review and metaanalysis of randomized controlled trials. Journal of Rheumatology, 2010. 37(10): p. 1991-2005.

152.  Falcao, D.M., et al., Cognitive behavioral therapy for the treatment of fibromyalgia syndrome: A randomized controlled trial. Journal of Musculoskeletal Pain, 2008. 16(3): p. 133-140.

153.  Suman, A.L., et al., One-year efficacy of a 3-week intensive multidisciplinary non-pharmacological treatment program for fibromyalgia patients. Clinical & Experimental Rheumatology, 2009. 27(1): p. 7-14.

154.  Goossens, M.E., et al., Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. II. Economic evaluation. Journal of Rheumatology, 1996. 23(7): p. 1246-54.

155.  Ang, D.C., et al., Cognitive-behavioral therapy attenuates nociceptive responding in patients with fibromyalgia: a pilot study. Arthritis Care & Research, 2010. 62(5): p. 618-23.

156.  Ang, D., et al., Exercise-based motivational interviewing for female patients with fibromyalgia: a case series. Clinical Rheumatology, 2007. 26(11): p. 1843-9.

157.  Bennett, R.M., et al., Group treatment of fibromyalgia: a 6 month outpatient program. Journal of Rheumatology, 1996. 23(3): p. 521-8.

158.  Creamer, P., et al., Sustained improvement produced by nonpharmacologic intervention in fibromyalgia: results of a pilot study. Arthritis Care & Research, 2000. 13(4): p. 198-204.

159.  Broderick, J.E., D.U. Junghaenel, and J.E. Schwartz, Written emotional expression produces health benefits in fibromyalgia patients. Psychosomatic Medicine, 2005. 67(2): p. 326-34.

160.  De Voogd, J.N., et al., Treatment of fibromyalgia syndrome with psychomotor therapy and marital counselling. Journal of Musculoskeletal Pain, 1993. 1(3-4): p. 273-281.

161.  Drexler, A.R., E.J. Mur, and V.C. Gunther, Efficacy of an EMG-biofeedback therapy in fibromyalgia patients. A comparative study of patients with and without abnormality in (MMPI) psychological scales. Clinical & Experimental Rheumatology, 2002. 20(5): p. 677-82.

162.  Kaplan, K.H., D.L. Goldenberg, and M. Galvin-Nadeau, The impact of a meditation-based stress reduction program on fibromyalgia. General Hospital Psychiatry, 1993. 15(5): p. 284-9.

163.  Worrel, L.M., et al., Treating fibromyalgia with a brief interdisciplinary program: initial outcomes and predictors of response. Mayo Clinic Proceedings, 2001. 76(4): p. 384-90.

164.  Fors, E.A., H. Sexton, and K.G. Gotestam, The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. Journal of Psychiatric Research, 2002. 36(3): p. 179-87.

165.  Castel, A., et al., Effect of hypnotic suggestion on fibromyalgic pain: comparison between hypnosis and relaxation. European Journal of Pain: Ejp, 2007. 11(4): p. 463-8.

166.  Menzies, V., A.G. Taylor, and C. Bourguignon, Effects of guided imagery on outcomes of pain, functional status, and self-efficacy in persons diagnosed with fibromyalgia. Journal of Alternative & Complementary Medicine, 2006. 12(1): p. 23-30.

167.  Bernardy, K., et al., Efficacy of hypnosis/guided imagery in fibromyalgia syndrome–a systematic review and meta-analysis of controlled trials. BMC Musculoskeletal Disorders, 2011. 12: p. 133.

168.  Hadhazy, V.A., et al., Mind-body therapies for the treatment of fibromyalgia. A systematic review. Journal of Rheumatology, 2000. 27(12): p. 2911-8.

169.  Carretero, B., et al., Low-frequency transcranial magnetic stimulation in patients with fibromyalgia and major depression. Pain Medicine, 2009. 10(4): p. 748-53.

170.  Short, E.B., et al., Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: A randomized, controlled pilot study. Pain, 2011. 152(11): p. 2477-84.

171.  Roizenblatt, S., et al., Site-specific effects of transcranial direct current stimulation on sleep and pain in fibromyalgia: a randomized, sham-controlled study. Pain Practice, 2007. 7(4): p. 297-306.

172.  Turk, D.C., J.P. Robinson, and T. Burwinkle, Prevalence of fear of pain and activity in patients with fibromyalgia syndrome. Journal of Pain, 2004. 5(9): p. 483-90.

173.  Bakker, C., et al., Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. Journal of Rheumatology, 1995. 22(7): p. 1304-10.

174.  Brosseau, L., et al., Ottawa Panel evidence-based clinical practice guidelines for strengthening exercises in the management of fibromyalgia: part 2. Phys Ther, 2008. 88(7): p. 873-86.

175.  Brosseau, L., et al., Ottawa Panel evidence-based clinical practice guidelines for aerobic fitness exercises in the management of fibromyalgia: part 1. Phys Ther, 2008. 88(7): p. 857-71.

176.  Busch, A., et al., Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev, 2002(3): p. CD003786.

177.  Busch, A.J., et al., Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev, 2007. (4)(4): p. CD003786.

178.  Busch, A.J., et al., Exercise for fibromyalgia: a systematic review. Journal of Rheumatology, 2008. 35(6): p. 1130-44.

179.  Ramel, J., et al., Exercise for Fibromyalgia Pain: A Meta-Analysis of Randomized Controlled Trials. Current Rheumatology Reviews, 2009. 5(4): p. 188-193.

180.  Baranowsky, J., et al., Qualitative systemic review of randomized controlled trials on complementary and alternative medicine treatments in fibromyalgia. Rheumatology International, 2009. 30(1): p. 1-21.

181.  Mannerkorpi, K., et al., Pool exercise for patients with fibromyalgia or chronic widespread pain: a randomized controlled trial and subgroup analyses. Journal of Rehabilitation Medicine, 2009. 41(9): p. 751-60.

182.  Tomas-Carus, P., et al., Aquatic training and detraining on fitness and quality of life in fibromyalgia. Medicine & Science in Sports & Exercise, 2007. 39(7): p. 1044-50.

183.  McVeigh, J.G., et al., The effectiveness of hydrotherapy in the management of fibromyalgia syndrome: a systematic review. Rheumatology International, 2008. 29(2): p. 119-30.

184.  Perraton, L., Z. Machotka, and S. Kumar, Components of effective randomized controlled trials of hydrotherapy programs for fibromyalgia syndrome: A systematic review. Journal of Pain Research, 2009. 2: p. 165-173.

185.  Langhorst, J., et al., Efficacy of hydrotherapy in fibromyalgia syndrome–a meta-analysis of randomized controlled clinical trials. Rheumatology (Oxford), 2009. 48(9): p. 1155-9.

186.  Altan, L., et al., Effect of pilates training on people with fibromyalgia syndrome: a pilot study. Arch Phys Med Rehabil, 2009. 90(12): p. 1983-8.

187.  Taggart, H.M., et al., Effects of T’ai Chi exercise on fibromyalgia symptoms and health-related quality of life. Orthopaedic Nursing, 2003. 22(5): p. 353-60.

188.  Wang, C., Tai chi and rheumatic diseases. Rheumatic Diseases Clinics of North America, 2011. 37(1): p. 19-32.

189.  Wang, C., et al., A randomized trial of tai chi for fibromyalgia. New England Journal of Medicine, 2010. 363(8): p. 743-54.

190.  da Silva, G.D., G. Lorenzi-Filho, and L.V. Lage, Effects of yoga and the addition of Tui Na in patients with fibromyalgia. Journal of Alternative & Complementary Medicine, 2007. 13(10): p. 1107-13.

191.  Nielens, H., V. Boisset, and E. Masquelier, Fitness and perceived exertion in patients with fibromyalgia syndrome. Clinical Journal of Pain, 2000. 16(3): p. 209-13.

192.  Verstappen, F.T.J., et al., Fitness characteristics of female patients with fibromyalgia. Journal of Musculoskeletal Pain, 1995. 3(3): p. 45-58.

193.  Pioro-Boisset, M., J.M. Esdaile, and M.A. Fitzcharles, Alternative medicine use in fibromyalgia syndrome. Arthritis Care and Research, 1996. 9(1): p. 13-17.

194.  Cao, H., J. Liu, and G.T. Lewith, Traditional Chinese Medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. Journal of Alternative & Complementary Medicine, 2010. 16(4): p. 397-409.

195.  De Silva, V., et al., Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review. Rheumatology (Oxford), 2010. 49(6): p. 1063-8.

196.  Perry, R., R. Terry, and E. Ernst, A systematic review of homoeopathy for the treatment of fibromyalgia. Clinical Rheumatology, 2010. 29(5): p. 457-64.

197.  Martin-Sanchez, E., et al., Efficacy of acupuncture for the treatment of fibromyalgia: Systematic review and meta-analysis of randomized trials. Open Rheumatology Journal, 2009. 3: p. 25-29.

198.  Mayhew, E. and E. Ernst, Acupuncture for fibromyalgia–a systematic review of randomized clinical trials. Rheumatology (Oxford), 2007. 46(5): p. 801-4.

199.  Berman, B.M., et al., Is acupuncture effective in the treatment of fibromyalgia? Journal of Family Practice, 1999. 48(3): p. 213-8.

200.  Langhorst, J., et al., Efficacy of acupuncture in fibromyalgia syndrome–a systematic review with a meta-analysis of controlled clinical trials. Rheumatology, 2010. 49(4): p. 778-88.

201.  Targino, R.A., et al., A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. Journal of Rehabilitation Medicine, 2008. 40(7): p. 582-8.

202.  Haak, T. and B. Scott, The effect of Qigong on fibromyalgia (FMS): a controlled randomized study. Disability & Rehabilitation, 2008. 30(8): p. 625-33.

203.  Ernst, E., Chiropractic treatment for fibromyalgia: a systematic review. Clinical Rheumatology, 2009. 28(10): p. 1175-8.

204.  Schneider, M., et al., Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. Journal of Manipulative & Physiological Therapeutics, 2009. 32(1): p. 25-40.

205.  Fitzcharles, M.A., et al., Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med, 2011. 124(10): p. 955-60.

206.  Hooten, W.M., et al., Treatment outcomes after multidisciplinary pain rehabilitation with analgesic medication withdrawal for patients with fibromyalgia. Pain Medicine, 2007. 8(1): p. 8-16.

207.  World Health Organization. WHO Pain Ladder. 1986  [cited 2011 22 November]; Available from:

208.  Bennett, R.M., et al., Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine, 2003. 114(7): p. 537-45.

209.  Guggenheimer, J. and P.A. Moore, The therapeutic applications of and risks associated with acetaminophen use: a review and update. Journal of the American Dental Association, 2011. 142(1): p. 38-44.

210.  Lynch, M.E. and C.P. Watson, The pharmacotherapy of chronic pain: a review. Pain Research & Management, 2006. 11(1): p. 11-38.

211.  Lynch, M.E., The pharmacotherapy of chronic pain. Rheumatic Diseases Clinics of North America, 2008. 34(2): p. 369-85.

212.  Chandrasekharan, N.V., et al., COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A, 2002. 99(21): p. 13926-31.

213.  Hogestatt, E.D., et al., Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem, 2005. 280(36): p. 31405-12.

214.  Bertolini, A., et al., Paracetamol: new vistas of an old drug. CNS Drug Rev, 2006. 12(3-4): p. 250-75.

215.  Wolfe, F., S. Zhao, and N. Lane, Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis and Rheumatism, 2000. 43 (2): p. 378-385.

216.  Bennett, R.M., et al., An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders, 2007. 8: p. 27.

217.  Kroenke, K., E.E. Krebs, and M.J. Bair, Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. General Hospital Psychiatry, 2009. 31(3): p. 206-219.

218.  Rao, S.G. and D.J. Clauw, The management of fibromyalgia. Drugs of Today, 2004. 40(6): p. 539-54.

219.  Tannenbaum, H., et al., An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. Journal of Rheumatology, 2006. 33(1): p. 140-57.

220.  Bjordal, J.M., et al., Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ, 2004. 329(7478): p. 1317.

221.  Trelle, S., et al., Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ, 2011. 342: p. c7086.

222.  White, W.B., et al., Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol, 2007. 99(1): p. 91-8.

223.  Soni, P., et al., The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Current Medical Research & Opinion, 2009. 25(8): p. 1841-51.

224.  Biasi, G., et al., Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. International Journal of Clinical Pharmacology Research, 1998. 18(1): p. 13-9.

225.  Furlan, A.D., et al., Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ Canadian Medical Association Journal, 2006. 174(11): p. 1589-94.

226.  Hauser, W., K. Thieme, and D.C. Turk, Guidelines on the management of fibromyalgia syndrome – a systematic review. European Journal of Pain: Ejp, 2010. 14(1): p. 5-10.

227.  Younger, J.W., A.J. Zautra, and E.T. Cummins, Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology. PLoS ONE [Electronic Resource], 2009. 4(4): p. e5180.

228.  Chen, Z.R., A.A. Somogyi, and F. Bochner, Polymorphic O-demethylation of codeine. Lancet, 1988. 2(8616): p. 914-5.

229.  Crofford, L.J., Adverse effects of chronic opioid therapy for chronic musculoskeletal pain. Nature Reviews Rheumatology, 2010. 6(4): p. 191-7.

230.  Hartung, D.M., et al., Rates of adverse events of long-acting opioids in a state Medicaid program. Ann Pharmacother, 2007. 41(6): p. 921-8.

231.  Manchikanti, L., et al., Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician, 2010. 13(5): p. 401-35.

232.  Okie, S., A flood of opioids, a rising tide of deaths. New England Journal of Medicine, 2010. 363(21): p. 1981-5.

233.  Furlan, A.D., R. Reardon, and C. Weppler, Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ Canadian Medical Association Journal, 2010. 182(9): p. 923-30.

234.  Chou, R., et al., Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. Journal of Pain, 2009. 10(2): p. 113-30.

235.  Campbell, F.A., et al., Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ, 2001. 323(7303): p. 13-6.

236.  Lynch, M.E. and F. Campbell, Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol, 2011. 72(5): p. 735-44.

237.  Pertwee, R.G., Cannabinoid receptors and pain. Prog Neurobiol, 2001. 63(5): p. 569-611.

238.  Skrabek, R.Q., et al., Nabilone for the treatment of pain in fibromyalgia. Journal of Pain, 2008. 9(2): p. 164-73.

239.  Ware, M.A., et al., The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg, 2010. 110(2): p. 604-10.

240.  Arnold, L.M., P.E. Keck, Jr., and J.A. Welge, Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics, 2000. 41(2): p. 104-13.

241.  Crofford, L.J., Meta-analysis of antidepressants in fibromyalgia. Curr Rheumatol Rep, 2001. 3(2): p. 115.

242.  O’Malley, P.G., et al., Treatment of fibromyalgia with antidepressants: a meta-analysis. Journal of General Internal Medicine, 2000. 15(9): p. 659-66.

243.  Hauser, W., et al., Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA, 2009. 301(2): p. 198-209.

244.  Lunn, M.P., R.A. Hughes, and P.J. Wiffen, Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev, 2009(4): p. CD007115.

245.  Nishishinya, B., et al., Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology, 2008. 47(12): p. 1741-6.

246.  Perrot, S., et al., Is there any evidence to support the use of anti-depressants in painful rheumatological conditions? Systematic review of pharmacological and clinical studies. Rheumatology, 2008. 47(8): p. 1117-23.

247.  Sultan, A., et al., Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol, 2008. 8(29): p. 29.

248.  Uceyler, N., W. Hauser, and C. Sommer, A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Care and Research, 2008. 59 (9): p. 1279-1298.

249.  Goldenberg, D.L., D.J. Clauw, and M.A. Fitzcharles, New concepts in pain research and pain management of the rheumatic diseases. Seminars in Arthritis & Rheumatism, 2011. 41(3): p. 319-34.

250.  Heymann, R.E., M. Helfenstein, and D. Feldman, A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clinical & Experimental Rheumatology, 2001. 19(6): p. 697-702.

251.  Tofferi, J.K., J.L. Jackson, and P.G. O’Malley, Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis & Rheumatism, 2004. 51(1): p. 9-13.

252.  Arnold, L.M., et al., Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Clinical Journal of Pain, 2009. 25(6): p. 461-8.

253.  Chappell, A.S., et al., A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clinical Journal of Pain, 2009. 25(5): p. 365-75.

254.  Choy, E.H.S., et al., Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clinical Rheumatology, 2009. 28(9): p. 1035-44.

255.  Boulanger, L., et al., Predictors of Pain Medication Selection Among Patients Diagnosed with Fibromyalgia. Pain Pract, 2011.

256.  Rasmussen, P. and J. Riishede, Facial pain treated with carbamazepin (Tegretol). Acta Neurol Scand, 1970. 46(4): p. 385-408.

257.  Rogawski, M.A. and W. Loscher, The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med, 2004. 10(7): p. 685-92.

258.  Sills, G.J., The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol, 2006. 6(1): p. 108-13.

259.  Hauser, W., et al., Treatment of fibromyalgia syndrome with gabapentin and pregabalin–a meta-analysis of randomized controlled trials. Pain, 2009. 145(1-2): p. 69-81.

260.  Siler, A.C., et al., Systematic review of the comparative effectiveness of antiepileptic drugs for fibromyalgia. Journal of Pain, 2011. 12(4): p. 407-15.

261.  Holtedahl, R., [Questionable documentation of the effect of pregabalin in fibromyalgia]. Tidsskr Nor Laegeforen, 2010. 130(10): p. 1032-6.

262.  Moore, R.A., et al., Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev, 2009(3): p. CD007076.

263.  Randinitis, E.J., et al., Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Journal of Clinical Pharmacology, 2003. 43(3): p. 277-283.

264.  Sun, P., et al., Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia. Current Medical Research & Opinion, 2011. 27(9): p. 1793-801.

265.  Gore, M., et al., Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Practice, 2009. 9(5): p. 363-74.

266.  Holman, A.J. and R.R. Myers, A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis & Rheumatism, 2005. 52(8): p. 2495-505.

267.  Distler, O., et al., Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & Rheumatism, 2010. 62(1): p. 291-300.

268.  Weintraub, D., et al., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol, 2010. 67(5): p. 589-95.

269.  Wu, Y., et al., Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology, 2004. 47(8): p. 1146-56.

270.  Russell, I.J., et al., Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism, 2009. 60(1): p. 299-309.

271.  Scharf, M.B., M. Baumann, and D.V. Berkowitz, The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. Journal of Rheumatology, 2003. 30(5): p. 1070-4.

272.  Staud, R., Sodium oxybate for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy, 2011. 12(11): p. 1789-98.

273.  Vergne-Salle, P., et al., A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia. European Journal of Pain: Ejp, 2011. 15(5): p. 509-14.

274.  Farber, L., et al., Efficacy and tolerability of tropisetron in primary fibromyalgia–a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scandinavian Journal of Rheumatology – Supplement, 2000. 113: p. 49-54.

275.  Haus, U., et al., Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scandinavian Journal of Rheumatology – Supplement, 2000. 113: p. 55-8.

276.  Olin, R., R. Klein, and P.A. Berg, A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. Clinical Rheumatology, 1998. 17(2): p. 89-94.

277.  Graven-Nielsen, T., et al., Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain, 2000. 85(3): p. 483-91.

278.  McCleane, G., Does intravenous lidocaine reduce fibromyalgia pain?: A randomized, double-blind, placebo controlled cross-over study. The Pain Clinic, 2000. 12(3): p. 181-185.

279.  Staud, R., et al., Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain, 2009. 145(1-2): p. 96-104.

280.  Affaitati, G., et al., Effects of treatment of peripheral pain generators in fibromyalgia patients. European Journal of Pain: Ejp, 2011. 15(1): p. 61-9.

281.  Castro-Sanchez, A.M., et al., Effects of myofascial release techniques on pain, physical function, and postural stability in patients with fibromyalgia: a randomized controlled trial. Clinical Rehabilitation, 2011. 25(9): p. 800-13.

282.  Ko, G.D., et al., Effective Pain Palliation in Fibromyalgia Syndrome Patients with Botulinum Toxin Type-A: Case Series of 25. Journal of Musculoskeletal Pain, 2007. 15(4): p. 55-66.

283.  Paulson, G.W. and W. Gill, Botulinum toxin is unsatisfactory therapy for fibromyalgia. Movement Disorders, 1996. 11(4): p. 459.

284.  Finckh, A., et al., A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. Journal of Rheumatology, 2005. 32(7): p. 1336-40.

285.  Russell, I.J., et al., Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. Journal of Interferon & Cytokine Research, 1999. 19(8): p. 961-8.

286.  Kendall, S.A., et al., No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. Journal of Rheumatology, 2004. 31(4): p. 783-4.

287.  Bennett, R.M., S.C. Clark, and J. Walczyk, A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. American Journal of Medicine, 1998. 104(3): p. 227-31.

288.  Cuatrecasas, G., et al., Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskeletal Disorders, 2007. 8: p. 119.

289.  Drewes, A.M., et al., Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scandinavian Journal of Rheumatology, 1991. 20(4): p. 288-93.

290.  Gronblad, M., et al., Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clinical Rheumatology, 1993. 12(2): p. 186-91.

291.  Quijada-Carrera, J., et al., Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain, 1996. 65(2-3): p. 221-5.

292.  Hidalgo, J., F. Rico-Villademoros, and E.P. Calandre, An open-label study of quetiapine in the treatment of fibromyalgia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2007. 31(1): p. 71-7.

293.  Citera, G., et al., The effect of melatonin in patients with fibromyalgia: a pilot study. Clinical Rheumatology, 2000. 19(1): p. 9-13.

294.  Wolfe, F., et al., Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Journal of Rheumatology, 2011. 38(6): p. 1113-22.

295.  Penrod, J.R., et al., Health services costs and their determinants in women with fibromyalgia. Journal of Rheumatology, 2004. 31(7): p. 1391-8.

296.  Wang, F., et al., Early improvement in pain predicts pain response at endpoint in patients with fibromyalgia. Journal of Pain, 2011. 12(10): p. 1088-94.

297.  Fitzcharles, M.-A., D.D. Costa, and R. Poyhia, A study of standard care in fibromyalgia syndrome: a favorable outcome. Journal of Rheumatology, 2003. 30(1): p. 154-9.

298.  Granges, G., P. Zilko, and G.O. Littlejohn, Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. Journal of Rheumatology, 1994. 21(3): p. 523-9.

299.  Martinez, J.E., et al., Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. Journal of Rheumatology, 1995. 22(2): p. 270-4.

300.  MacFarlane, G.J., et al., The natural history of chronic pain in the community: a better prognosis than in the clinic? Journal of Rheumatology, 1996. 23(9): p. 1617-20.

301.  Turk, D.C., et al., Effects of type of symptom onset on psychological distress and disability in fibromyalgia syndrome patients. Pain, 1996. 68(2-3): p. 423-30.

302.  Campos, R.P. and M.I. Vazquez, Health-related quality of life in women with fibromyalgia: clinical and psychological factors associated. Clin Rheumatol, 2011.

303.  Martinez, M.P., et al., The relationship between the fear-avoidance model of pain and personality traits in fibromyalgia patients. J Clin Psychol Med Settings, 2011. 18(4): p. 380-91.

304.  Kim, C.H., et al., The association of body mass index with symptom severity and quality of life in patients with fibromyalgia. Arthritis Care & Research, 2011.

305.  Geisser, M.E., et al., Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain, 2010. 149(2): p. 373-8.

306.  Bakker, C., et al., Patient utilities in fibromyalgia and the association with other outcome measures. Journal of Rheumatology, 1995. 22(8): p. 1536-43.

307.  Bennett, R.M., et al., The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther, 2009. 11(4): p. R120.

308.  Burckhardt, C.S., S.R. Clark, and R.M. Bennett, The fibromyalgia impact questionnaire: development and validation. Journal of Rheumatology, 1991. 18(5): p. 728-33.

309.  Bennett, R., The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clinical & Experimental Rheumatology, 2005. 23(5 Suppl 39): p. S154-62.

310.  Bruce, B. and J.F. Fries, The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health & Quality of Life Outcomes, 2003. 1: p. 20.

311.  Bennett, R.M., et al., Minimal clinically important difference in the fibromyalgia impact questionnaire. Journal of Rheumatology, 2009. 36(6): p. 1304-11.

312.  Martinez, J.E., et al., Evaluation of the quality of life in Brazilian women with fibromyalgia, through the medical outcome survey 36 item short-form study. Disability & Rehabilitation, 2001. 23(2): p. 64-8.

313.  Wewers, M.E. and N.K. Lowe, A critical review of visual analogue scales in the measurement of clinical phenomena. Research in Nursing & Health, 1990. 13(4): p. 227-36.

314.  Bigatti, S.M. and T.A. Cronan, A comparison of pain measures used with patients with fibromyalgia. Journal of Nursing Measurement, 2002. 10(1): p. 5-14.

315.  Farrar, J.T., et al., The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. Journal of Pain, 2010. 11(2): p. 109-18.

316.  Staud, R., et al., Body pain area and pain-related negative affect predict clinical pain intensity in patients with fibromyalgia. Journal of Pain, 2004. 5(6): p. 338-43.

317.  Harris, R.E., et al., Comparison of clinical and evoked pain measures in fibromyalgia. Journal of Pain, 2006. 7(7): p. 521-7.

318.  Wolfe, F., et al., Work and disability status of persons with fibromyalgia. Journal of Rheumatology, 1997. 24(6): p. 1171-8.

319.  White, D.H.N., K. Faull, and P.B.B. Jones, An exploratory study of long-term health outcomes following an in-patient multidisciplinary program for people with fibromyalgia syndrome. International Journal of Rheumatic Diseases, 2009. 12(1): p. 52-6.

320.  Reisine, S., et al., Do employment and family work affect the health status of women with fibromyalgia? Journal of Rheumatology, 2003. 30(9): p. 2045-53.

321.  Reisine, S., et al., Employment and health status changes among women with fibromyalgia: A five-year study. Arthritis Care and Research, 2008. 59 (12): p. 1735-1741.

322.  Perrot, S., et al., Characteristics of patients with fibromyalgia in France and Germany. International Journal of Clinical Practice, 2010. 64 (8): p. 1100-1108.

323.  Silverman, S., et al., The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Current Medical Research & Opinion, 2009. 25(4): p. 829-40.

324.  Henriksson, C.M., G.M. Liedberg, and B. Gerdle, Women with fibromyalgia: work and rehabilitation. Disability & Rehabilitation, 2005. 27(12): p. 685-94.

325.  van Koulil, S., et al., Tailored cognitive-behavioural therapy and exercise training improves the physical fitness of patients with fibromyalgia. Annals of the Rheumatic Diseases, 2011. 70(12): p. 2131-3.

326.  Skouen, J.S., A. Grasdal, and E.M.H. Haldorsen, Return to work after comparing outpatient multidisciplinary treatment programs versus treatment in general practice for patients with chronic widespread pain. European Journal of Pain: Ejp, 2006. 10(2): p. 145-52.

327.  Rutledge, D.N., K. Jones, and C.J. Jones, Predicting high physical function in people with fibromyalgia. Journal of Nursing Scholarship, 2007. 39(4): p. 319-24.

328.  Kurtze, N., K.T. Gundersen, and S. Svebak, The impact of perceived physical dysfunction, health-related habits, and affective symptoms on employment status among fibromyalgia support group members. Journal of Musculoskeletal Pain, 2001. 9 (2): p. 39-53.

329.  Boonen, A., et al., Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Annals of the Rheumatic Diseases, 2005. 64(3): p. 396-402.

330.  Rivera, J., et al., Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Clinical & Experimental Rheumatology, 2009. 27(5 Suppl 56): p. S39-45.

331.  Wolfe, F., et al., A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis & Rheumatism, 1997. 40(9): p. 1560-70.

332.  Berger, A., et al., Characteristics and healthcare costs of patients with fibromyalgia syndrome. International Journal of Clinical Practice, 2007. 61(9): p. 1498-508.

333.  Oliver, K., et al., Effects of social support and education on health care costs for patients with fibromyalgia. Journal of Rheumatology, 2001. 28(12): p. 2711-9.

334.  Sicras-Mainar, A., et al., Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Arthritis Res Ther, 2009. 11(2): p. R54.

335.  Walen, H.R., P.A. Cronan, and S.M. Bigatti, Factors associated with healthcare costs in women with fibromyalgia. American Journal of Managed Care, 2001. 7 Spec No: p. SP39-47.

336.  Robinson, R.L., et al., Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. Journal of Rheumatology, 2004. 31(8): p. 1621-9.

1 Division of Rheumatology, McGill University, Montreal, Quebec, Canada
2Alan Edwards Pain Management Unit, McGill University Health Center, Montreal, Quebec, Canada
3Faculty of Law, Université de Montréal, Montreal, Quebec, Canada
4Division of Rheumatology, Tufts University School of Medicine, Boston, Massachusetts, USA
5Department of Family Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
6Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
7Centre de la recherche du Centre hospitalier de l’Université de Montréal; Department of Anesthesiology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
8Division of Physiatry, University of Toronto, Toronto, Ontario, Canada
9Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario, London, Ontario, Canada
10Patient representative